AMLN Amylin Pharmaceuticals, Inc. (MM)

SAN DIEGO, Dec. 22 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) is honored to be recognized with three prestigious awards for biotechnology excellence, product innovation, and leadership. Earlier this month, Amylin won the inaugural Scrip Award for Biotechnology Company of the Year. In addition, SYMLIN(R) (pramlintide acetate) injection won the CONNECT Award for Most Innovative New Product in the area of Life Science Therapeutics, and earlier this year Ginger L. Graham, President and Chief Executive Officer of Amylin, was awarded the Emerging Company Executive of the Year at the 2005 Pharmaceutical Achievement Awards. Amylin won the Scrip Award for obtaining approval for two first-in-class medicines for the treatment of diabetes. Other companies nominated for the Biotech of the Year award were Genzyme and Serono. Amylin, with its collaborative partner Eli Lilly and Company, also received Scrip Award nominations in the categories of Best New Drug and Speed to Market for the recently approved drug BYETTA(R) (exenatide) injection. Hosted by PJB Publications, the publishers of Scrip World Pharmaceuticals News, the Scrip Awards are designed to recognize the excellent work taking place throughout the pharmaceutical and biotech industries globally, and give publicity to the many in pharmaceutical and biotech companies who routinely excel. SYMLIN, approved by the FDA in March 2005, won the CONNECT Most Innovative New Product (MIP) award in the area of Life Science Therapeutics. The only other nominee in this category was Amylin's second product, BYETTA, which was approved in April 2005. Since 1988, the CONNECT MIP Awards have been awarded to innovative new products for companies based in San Diego. CONNECT is an organization originally founded by the University of California, San Diego to help bring the creators of new technologies together with business in order to promote the development of new technologies and medicines. "These awards represent 18 years of hard work, passion, and focus on patient needs by our dedicated employees that resulted in two first-in-class therapies now available to help people manage their diabetes," said Ginger Graham, president and CEO of Amylin Pharmaceuticals. Ginger Graham won the Emerging Company Executive of the Year award at the Fourth Annual Pharmaceutical Achievement Awards held in August, which recognize the significant accomplishments of individuals and organizations in the global pharmaceutical and biotechnology industries in the areas of science, business and corporate generosity. The awards were designed with the broad support and unbiased contributions of industry and academic advisors, a well respected international accounting firm and the production team of IBC Life Sciences Group, part of T&F Informa. About Amylin Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development, and commercialization of innovative medicines. This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. The Company's actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA and/or SYMLIN may not prove to be important new therapeutic options or may be affected by unexpected new data or technical issues. Commercial and government reimbursement and pricing decisions, the pace of market acceptance and any issues related to manufacturing and supply may also affect the potential for BYETTA and/or SYMLIN. These and additional risks and uncertainties are described more fully in the Company's most recently filed SEC documents, including its Form 10-Qs. Amylin undertakes no duty to update these forward-looking statements. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Mark Foletta, VP, Finance and CFO of Amylin Pharmaceuticals, Inc., +1-858-552-2200

Copyright